ArticlePediatric nephrology (Berlin, Germany)2009
Post-transplant lymphoproliferative disease.
Article in Pediatric nephrology (Berlin, Germany), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 86 citations in OpenAlex.
- Time Is Key: Early Diagnosis of Post-Transplant Lymphoproliferative Disorder Presenting as Primary CNS Diffuse Large B-Cell Lymphoma.Current oncology (Toronto, Ont.) · 2026Article
- EBV Genome Variations and Association With Diseases.Journal of medical virology · 2026Review
- Gastrointestinal-localized polymorphic post-transplant lymphoproliferative disorder following kidney transplantation after allogeneic hematopoietic stem cell transplantation: a rare case report.Clinical journal of gastroenterology · 2026Article
- A Case of Post-Transplantation Lymphoproliferative Disorder Following Kidney Transplantation.Case reports in nephrology · 2026Article
- LMP2A-Targeting CAR-T Cells Equipped With Inducible IL-18 to Address EBV-Associated Malignancies.HLA · 2025Article
- Prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2025Article
- The Post-transplant Lymphoproliferative Disorders-Metagenomic Shotgun Microbial Sequencing (PTLD-MSMS) Study Methods and Protocol.Transplantation direct · 2024Article
- Post-Transplant Lymphoproliferative Disorders.Seminars in nephrology · 2024Review
- Pre-Existing Intrarenal Parvovirus B19 Infection May Relate to Antibody-Mediated Rejection in Pediatric Kidney Transplant Patients.International journal of molecular sciences · 2023Article
- A rare case of post-transplant lymphoproliferative disorder (Hodgkins lymphoma) post autologous stem cell transplantation: A case report and review of literature.Annals of medicine and surgery (2012) · 2022Article
- Incidence of malignancy after pediatric kidney transplantation: a single-center experience over the past three decades in Japan.Clinical and experimental nephrology · 2022Article
- Biomarkers for PTLD diagnosis and therapies.Pediatric nephrology (Berlin, Germany) · 2020Review
- Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients.Pediatric nephrology (Berlin, Germany) · 2020Article
- Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders.Cancer medicine · 2019Article
- Non-immunologic allograft loss in pediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2019Review
- Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.Pediatric nephrology (Berlin, Germany) · 2017Article
- Clinical and Economic Consequences of Early Cancer After Kidney Transplantation in Contemporary Practice.Transplantation · 2017Article
- Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation.Pediatric cardiology · 2015Article
- Tofacitinab in renal transplantation.Transplantation reviews (Orlando, Fla.) · 2013Review
- Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease.Pediatric nephrology (Berlin, Germany) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-transplant lymphoproliferative disease (PTLD) emerged in the mid-1990s as a major graft- and life-threatening complication of pediatric kidney transplantation. This condition, usually involving uncontrolled B lymphocyte proliferation, straddles the border between infection and malignancy, since Epstein-Barr virus (EBV) is intimately associated with the pathogenesis. PTLD is seen more in younger children (more likely to be EBV seronegative), Caucasian race, and in association with the more potent immunosuppression drugs. The clinical presentation typically involves multiple enlarged lymph nodes but varies based on localization of the lymphadenopathy. The diagnosis is based primarily on histopathological features. Treatment strategies include reduction of immunosuppression, use of anti-B cell antibodies, infusion of EBV-specific cytotoxic T lymphocytes, and chemotherapy. Many different strategies have been tried to prevent PTLD, ranging from serial EBV viral load monitoring and pre-emptive immunosuppression reduction to anti-viral prophylaxis. None of the major treatment or prevention strategies has been subject to randomized clinical trials, so their relative efficacy is still unknown. PTLD remains a risk factor for graft loss, though re-transplants have not, to date, been associated with repeat PTLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.